Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0278488 (metastatic breast cancer)
 7,812 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

What should be the standard treatment for taxane-refractory metastatic breast cancer remains controversial. In this paper, a case in which the 5'-DFUR + CPA + THP therapy was effective for paclitaxel-refractory metastatic breast cancer is reported. A 41-year-old female received pectoral muscle preserved mastectomy under diagnosis of the left breast cancer in May 1996. In June, 1999, a coin lesion of 2.2 cm diameter was found in the left middle lung field with chest X-ray. Paclitaxel 210 mg/m2 (once for three weeks, 8 cycles in total) resulted in marked improvement. The regimen of paclitaxel 70 mg/m2 (medication consecutive once-weekly for three weeks, and withdrawal for next week; 1 cycle) was carried out continuously with the patient ambulatory. Because resistance to the treatment appeared at the time the total dose reached 2,700 mg, 5'-DFUR + CPA + THP therapy (THP 30 mg/m2 (i.v.) x day 1, CPA 77 mg/m2 (p.o.) x 14 days, 5'-DFUR 460 mg/m2 (p.o.) x 14 days; 3 weeks with 1 cycle) was carried out, and definite improvement in the lung findings were observed. 5'-DFUR + CPA + THP therapy may be of use as a second-line therapy in paclitaxel-refractory recurrent breast cancer.
 ...
PMID:[A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report]. 1181 65

Taxanes (TX) were administered to 246 of 292 patients with recurrent/metastatic breast cancer (MBC) who were treated in Hiei Hospital between January 2001 and May 2006. Recently, TX has been increasingly prescribed for preoperative treatment and postoperative adjuvant therapy. To improve the prognosis of MBC, regimens effective for TX-resistant cancer patients should be developed. In this study, with respect to hormone receptor (HR) and Her 2/neu (HER 2), we retrospectively investigated whether our series responded to the regimens used after TX resistance was acquired. As post TX-resistance therapy (trastuzumab was combined in HER2-positive patients), 387 treatment regimens were administered to 166 patients. The following regimens achieved a response rate (patients achieving PR or CR/patients who could be evaluated) of 10% or more: combination therapy with TX and capecitabine (11/61, 18%), CPT-11 (10/57, 17.5%), vinorelbine (5/46, 10.9%), MFL-P (continuous treatment with MTX, 5-FU, LV, and CDDP) (12/47, 25.5%), and DMpC (5'-DFUR, MPA, CPA p.o.) (5/16, 31.2%). The latter 2 regimens achieved a high response rate,and some HR (-) and HER 2 (-) patients also responded to these regimens. In HR (+) or HER 2 (+) patients who responded to TX, survival was longer than that of non-responders. However, there was no difference in the treatment responsiveness of post-TX regimens between TX-responders and non-responders, suggesting the survival-prolonging effect of TX.
 ...
PMID:[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer]. 1763 40

The so-called triple-negative (TN) metastatic breast cancer (MBC), that is, MBC expressing no hormone receptors or HER2 protein, has attracted attention because of its low response rate to drug therapy and poor prognosis after recurrence. Of 423 MBC patients in our hospital in and after 2001, 54 had TN tumors. The median survival time (MST) of TN patients (25 months) was shorter than the MSTs of HR (+)/HER2 (-), HR (+)/HER2 (+), and HR (-)/HER2 (+) patients (69, 58, and 39 months, respectively). A retrospective analysis of responses to 162 regimens in 54 TN-MBC patients showed that anthracycline regimens produced a response rate of 18. 8% (a PR or higher response in 3 of 16 patients), whereas a taxane regimen yielded a very low response rate of 8. 1% (3/37). A similar low response was observed in monotherapy with MTX, CPT-11, VNR, gemcitabine, or S-1. Of particular note were the high response rate (46. 2%, 12/26) of DMpC therapy (oral 5'-DFUR, MPA, and CPA) and that (28%, 7/25) of MFL-P therapy (MTX, 5-FU, leucovorin, and CDDP), although these were not standard therapies. In addition, the molecular-targeted drug bevacizumab or cetuximab was concomitantly used with chemotherapeutic agents in 3 patients, and 1 each treated with either therapy achieved a PR. Thus, in the future, we can expect further advances in molecular-targeted therapy while using DMpC and MFL-P for the treatment of TN-MBC as an early-line therapy.
 ...
PMID:[Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer]. 2064 6